Dianthus Therapeutics’ (DNTH) primary asset is DNTH103, a selective monoclonal antibody targeting the active form of complement C1s. The main focus is a me-better version of Sanofi’s already-marketed C1s monoclonal antibody, Sutimlimab.Read More…
In 2013, experts reached a consensus to adopt the term C3 glomerulopathy (C3G) to define a group of rare kidney diseases driven by dysregulation of the alternative complement pathway, mediated by geneticRead More…
There are three complement activation pathways in the complement system, that is, the classical pathway, the alternative pathway, and the lectin pathway. The three pathways have different origins, but they cross eachRead More…
With the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still ongoing, the prevention and treatment of COVID-19 has become a research focus inRead More…
On February 4, 2022, Sanofi announced that its complement C1s antibody Sutimlimab was approved by the FDA for the treatment of cold agglutinin disease (CAD) under the trade name Enjaymo. Sutimlimab isRead More…